For Sponsors accustomed to the structured world of clinical trials, stepping into expanded access can feel deceptively familiar. Both involve investigational medicinal products. Both require regulatory engagement. Both carry inherent risks while the product’s safety and efficacy are still under evaluation. But the similarities largely end there, and misunderstanding where they diverge can create serious friction, delays, and misaligned expectations at the very moment patients need access most.
This article is written for Sponsors who are either new to Expanded Access Programs (EAPs) or transitioning from a clinical trial mindset into the access space. Understanding the fundamental differences between these two program types, particularly the nature of regulatory oversight in EAPs, is not just useful background knowledge. It is essential to running a successful program.
The Clinical Trial Framework: Built for Precision and Uniformity
Clinical trials operate within one of the most rigorously codified regulatory environments in the pharmaceutical industry. The Sponsor, via a protocol, determines the rules of the study, meaning the population and endpoints are pre-specified. Regulatory requirements – from ICH E6(R3) Good Clinical Practice to FDA 21 CFR Part 312 to the EU Clinical Trials Regulation (Regulation (EU) No 536/2014) – are detailed, consistent, and largely harmonized across major markets.
When a Sponsor submits a clinical trial application, they know what to expect. Feedback from regulators follows established processes. Approval pathways are defined. If the protocol is well-constructed and the data package is sound, the regulatory journey, while never trivial, is at least predictable. This predictability is by design. Clinical trials are scientific instruments, and their value depends on standardization, reproducibility, and the integrity of the data they generate. The regulatory framework reflects this. The rules are necessarily more prescriptive, with a greater emphasis on consistency and control.
Expanded Access Programs: A Fundamentally Different Beast
EAPs are intended to provide access to promising treatments for patients with serious or life-threatening conditions who have no satisfactory therapeutic alternatives and are unable to participate in a clinical trial (US FDA Expanded Access framework 21 CFR 312.305; Article 83 of Regulation (EC) No 726/2004).
In an EAP, the applicable regulations establish the conditions under which an unauthorized medicinal product may be supplied before marketing authorization. Regulatory authorities assess the available benefit-risk data, typically informed by completed or ongoing clinical trials, before permitting patient access. As a result, EAPs are generally available at later stages of product development, most commonly following encouraging Phase II data or during Phase III clinical development, when sufficient evidence exists to support a favorable benefit-risk assessment. In contrast to clinical trials, the Sponsor’s responsibilities are oriented primarily towards enabling treatment access rather than generating protocol-driven efficacy data. These responsibilities may include supplying the product, supporting treating physicians or hospitals, maintaining appropriate safety oversight and informing regulators when new information could affect the benefit-risk balance. In EAPs, data collection is generally more limited than in clinical trials and may focus primarily on safety and treatment outcomes required under the applicable pathway.
That distinction in purpose produces a fundamentally different regulatory environment.
EAP regulations are not globally harmonized, and they vary significantly from country to country. Some markets have dedicated legal frameworks for expanded access. Others route access through named patient, import permit or hospital exemption pathways. Some require individual patient applications approved case by case. Others permit cohort-level programs. The documentation requirements, timelines, fee structures, and submission formats differ accordingly.
More importantly – and this is where Sponsors with a clinical trial background often find themselves caught off guard – the regulations governing EAPs are not static, and the application of those regulations is not always uniform.
The Grey Zone: Why EAP Regulatory Feedback Can Shift
In a clinical trial, a regulatory authority reviews a protocol against a defined standard and responds accordingly. The criteria are codified. The process is structured. While regulatory feedback may require significant protocol revisions, it is generally grounded in well-defined requirements and established regulatory expectations.
In expanded access, the situation is often more complex. Medicinal products may be supplied to patients through one or multiple pathways, and the appropriate pathway will depend on several factors, including the product’s stage of development, the available clinical data, and the Sponsor’s marketing strategy.
Authorization decisions are based largely on the data generated during clinical development, but regulators may differ in how they assess the available evidence and the overall benefit-risk balance required to permit access to an investigational product.
Health Canada’s Special Access Program is a useful example of a mature national pathway whose practical application must account for the circumstances of each request. Feedback may reflect evolving evidence, program-specific considerations or changes in how a pathway is being interpreted and applied. As a result, similar requests submitted at different points may receive materially different feedback.
This is not a failure of the regulatory system. It is an inherent feature of a framework that is intentionally designed to be adaptive, to allow regulators to respond to novel situations, emerging safety signals, and the specific circumstances of individual patients and programs. But it does mean that Sponsors entering the EAP space with expectations calibrated to the clinical trial world will encounter a different kind of regulatory dialogue – one that requires flexibility, ongoing monitoring, and a willingness (and ability) to pivot.
What This Means in Practice for Sponsors
The consequences of misunderstanding this distinction are real. Sponsors can find themselves:
- Frustrated by apparent inconsistency, when in fact the regulatory landscape has evolved or a more nuanced read of the program specifics is required
- Slow to respond, because the internal decision-making structure isn’t built to accommodate rapid pivots in regulatory strategy
- At risk of delays in patient access, because the program has stalled at a regulatory junction that a more adaptive approach could have navigated
- Misattributing regulatory complexity to vendor failure, when the real issue is a structural mismatch between clinical trial expectations and access program realities
The last point is particularly important. When regulatory feedback shifts or a submission requires a significant pivot, it can look, from the outside, like the vendor didn’t know what they were doing. In reality, it often reflects the nature of the regulatory environment itself. A vendor that responds quickly, transparently, and with a well-reasoned new approach is demonstrating exactly the kind of expertise the access space demands.
The Case for a Specialist EAP Partner
Given the fluid nature of EAP regulations, the question Sponsors should be asking is not simply: “Does this vendor know the regulations?” It is: “Does this vendor continuously monitor how those regulations are being applied, and can they move fast when the ground shifts?”
This is a meaningfully different capability. It requires dedicated regulatory intelligence functions – teams that are tracking not just published guidance, but real-world regulatory feedback across multiple markets and programs. It requires relationships with health authorities built over years of active engagement. And it requires a program management structure that is built for agility, not just compliance.
At WEP Clinical, regulatory intelligence is not a background function; it is a core part of how we run every program. We operate across more than 150 countries, which means we are receiving live regulatory feedback from health authorities globally, continuously. When a regulatory body’s interpretation of a compassionate use pathway shifts, we see it, not in retrospect, but in real time, as it happens across our active programs. That intelligence feeds directly into how we advise Sponsors and how we structure submissions.
The ability to pivot is not a contingency plan. In expanded access, it is the plan.
A Different Kind of Partnership
For Sponsors used to the relative predictability of clinical trial regulation, EAPs ask something different of you and your vendor. They require a more flexible approach to strategy: programs must be robust enough to serve patients effectively, but nimble enough to respond as evidence, policy and individual circumstances evolve.
That doesn’t mean uncertainty is inevitable or that programs should be reactive by default. The best EAP programs are proactive precisely because they are run by teams that understand the regulatory landscape deeply enough to anticipate where it might move and have the experience to respond decisively when it does.”
WEP Clinical is a global leader in Expanded Access Program management and clinical trial services, operating across more than 150 countries. To speak with our regulatory team about structuring your access program for success, click here to contact us.
